Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q28250892)
Watch
English
Oral treatment for multiple sclerosis
scientific article
In more languages
default for all languages
No label defined
No description defined
edit
Statements
instance of
scholarly article
0 references
title
Oral treatment for multiple sclerosis
(English)
0 references
main subject
multiple sclerosis
0 references
author
Joep Killestein
series ordinal
1
object named as
Joep Killestein
0 references
Chris Polman
series ordinal
3
object named as
Chris H Polman
0 references
author name string
Richard A Rudick
series ordinal
2
0 references
language of work or name
English
0 references
publication date
November 2011
0 references
published in
Lancet Neurology
0 references
volume
10
0 references
issue
11
0 references
page(s)
1026-34
0 references
cites work
Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Fingolimod is a potential novel therapy for multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Future clinical challenges in multiple sclerosis: Relevance to sphingosine 1-phosphate receptor modulator therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Emerging oral therapies in multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Oral fingolimod (FTY720) for relapsing multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Development of oral cladribine for the treatment of multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The clinical pharmacokinetics of cladribine
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cladribine in treatment of chronic progressive multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The treatment of chronic progressive multiple sclerosis with cladribine
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Multiple Sclerosis Therapies: Molecular Mechanisms and Future
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Insight into the mechanism of laquinimod action
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The changing face of multiple sclerosis clinical trial populations
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Anti-JC virus antibodies: implications for PML risk stratification
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S1474-4422(11)70228-9
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
3010809
Fatcat ID
release_klpjrx3uzfhxhjfxi267r4tx3i
1 reference
stated in
Fatcat
reference URL
https://api.fatcat.wiki/v0/release/klpjrx3uzfhxhjfxi267r4tx3i
retrieved
24 November 2022
based on heuristic
mapped directly with Wikidata item
OpenCitations bibliographic resource ID
3010809
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
3010809
PubMed publication ID
22014437
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit